Number 891 • September 2020

Removal of temporary benefit from the Alberta Drug Benefit List (ADBL)

Due to the shortage of Apo-Ibuprofen 300 mg Tablet (DIN 00441651) and Apo-Ibuprofen 400 mg Tablet (DIN 00506052) manufactured by Apotex Inc., Advil 200 mg Tablet (DIN 01933558) manufactured by Pfizer Consumer Healthcare was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Apotex Inc. has advised Alberta Blue Cross that the shortage of Apo-Ibuprofen 400 mg Tablet (DIN 00506052) has been resolved. These products were removed from the Critical Supply Product List **September 1, 2020**.

As a result, Advil 200 mg Tablet (DIN 01933558) will no longer be considered a temporary benefit for the ADBL after September 30, 2020.

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Sivem Pharmaceuticals ULC, Sandoz Canada Inc., and Teva Canada Limited that the shortages for Losartan 25 mg Tablet (DIN 02388790), Sandoz-Losartan 25 mg Tablet (DIN 02313332), and Teva-Losartan 25 mg Tablet (DIN 02380838) respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 30, 2020**. The following grouping was removed from the Critical Supply Product List **September 1, 2020**.

LOSARTAN POTASSIUM

25 MG TABLET

00002379058	APO-LOSARTAN	APX	\$ 0.1616
00002403323	AURO-LOSARTAN	AUR	\$ 0.1616
00002445964	BIO-LOSARTAN	BMD	\$ 0.1616
00002398834	JAMP-LOSARTAN	JPC	\$ 0.1616
00002388790	LOSARTAN	SIV	\$ 0.1616
00002405733	MINT-LOSARTAN	MPI	\$ 0.1616
00002309750	PMS-LOSARTAN	PMS	\$ 0.1616
00002313332	SANDOZ LOSARTAN	SDZ	\$ 0.1616
00002424967	SEPTA-LOSARTAN	SEP	\$ 0.1616
00002380838	TEVA-LOSARTAN	TEV	\$ 0.1616
00002182815	COZAAR	MFC	\$ 1.4140

Alberta Blue Cross has been advised by Sivem Pharmaceuticals ULC, Sandoz Canada Inc., and Teva Canada Limited that the shortages for Losartan 100 mg Tablet (DIN 02388812), Sandoz-Losartan 100 mg Tablet (DIN 02313359), and Teva-Losartan 100 mg Tablet (DIN 02357976) respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 30, 2020**. The following grouping was removed from the Critical Supply Product List **September 1, 2020**.

LOSARTAN POTASSIUM

100 MG TABLET

00002353512	APO-LOSARTAN	APX	\$ 0.1616
00002403358	AURO-LOSARTAN	AUR	\$ 0.1616
00002445980	BIO-LOSARTAN	BMD	\$ 0.1616
00002398850	JAMP-LOSARTAN	JPC	\$ 0.1616
00002388812	LOSARTAN	SIV	\$ 0.1616
00002405768	MINT-LOSARTAN	MPI	\$ 0.1616
00002309777	PMS-LOSARTAN	PMS	\$ 0.1616
00002313359	SANDOZ LOSARTAN	SDZ	\$ 0.1616
00002424983	SEPTA-LOSARTAN	SEP	\$ 0.1616
00002357976	TEVA-LOSARTAN	TEV	\$ 0.1616
00002182882	COZAAR	MFC	\$ 1.4140

Alberta Blue Cross has been advised Sanis Health Inc., Sandoz Canada Inc. and Teva Canada Limited that the shortages for Lisinopril/HCTZ (Type Z) 20 mg/25 mg Tablet (DIN 02362961), Sandoz-Lisinopril/HCT 20 mg/25 mg Tablet 100 mg Tablet (DIN 02302381) and Teva-Lisinopril/HCTZ (Type Z) 20 mg/25 mg Tablet (DIN 02301784), respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 5, 2020**. The following grouping was removed from the Critical Supply Product List **September 2, 2020**.

LISINOPRIL/ HYDROCHLOROTHIAZIDE

20 MG / 25 MG TABLET

00002362961	LISINOPRIL/HCTZ (TYPE Z)	SNS	\$ 0.2503
00002302381	SANDOZ LISINOPRIL HCT	SDZ	\$ 0.2503
00002301784	TEVA-LISINOPRIL/HCTZ (TYPE Z)	TEV	\$ 0.2503
00002045729	ZESTORETIC	AZC	\$ 1.1159

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit ab.bluecross.ca/providers/pharmacy-home.php**



